Japanese Pharma Giant Takeda Pours Rp 539 Billion into Building Plasma Bank in Indonesia

Japanese biopharmaceutical company Takeda is preparing an investment of US$30 million, or around Rp 539 billion, to develop the plasma-derived medicinal product (PODP) ecosystem in Indonesia.

The funds will be used to build a plasma bank network over the next two years. The Ministry of Investment and Downstreaming/BKPM targets the first plasma bank to begin operations in 2027.

Minister of Investment and Downstreaming/Head of BKPM Rosan P Roeslani said Takeda’s investment reflects growing confidence among global investors in Indonesia’s investment prospects, particularly in the high-tech health industry sector.

“This is a strategic investment that not only brings additional capital, but also opens opportunities for technology transfer, human resource development, and the creation of highly skilled jobs,” Rosan said in a written statement on Tuesday (14/7/2026).

Rosan said the partnership aligns with the economic transformation agenda through downstreaming across various strategic sectors, including health, aimed at boosting the competitiveness of the national industry and strengthening Indonesia’s position in the global supply chain.

Japan is one of Indonesia’s strategic investment partners. According to data from the Ministry of Investment and Downstreaming/BKPM, in the first quarter of 2026, Japan ranked fifth among Indonesia’s top investors, reaching US$1 billion.

Japan’s total realised investment between 2021 and Q1 2026 reached US$18.1 billion, with average growth of 13.2% and employment absorption of 299,460 workers. This forms a strong foundation for developing investment cooperation across priority sectors, including health.

Through this collaboration, the Government hopes Indonesia will not only improve public access to much-needed plasma-derived medicinal products, but also build a competitive, innovative, and sustainable biopharmaceutical industry ecosystem.